Engrail Therapeutics’ US$32 Million Extension Of Its Series A Financing

Hogan Lovells Engrail Therapeutics on the deal.

Engrail Therapeutics recently completed US$32 million extension of its Series A financing round, bringing the total to US$64 million for the round.

Engrail Therapeutics is a company focused on the acquisition, development and commercialization of patient-centric therapies for diseases affecting the nervous system. The company will use the proceeds from this round to finance the advancement of its pipeline, including its lead assets, ENX-101, ENX-102, and internal preclinical programs.

The Hogan Lovells team was led by corporate partner Nate Gallon (Picture – Silicon Valley) and senior associate Christian Coyne (San Francisco).

Involved fees earner: Christian Coyne – Hogan Lovells; Nathaniel Gallon – Hogan Lovells;

Law Firms: Hogan Lovells;

Clients: Engrail Therapeutics, Inc.;

Author: Martina Bellini